Omkar Speciality Chemicals: FY26 Q1-Q3 Zero Sales

What the latest disclosures show

Omkar Speciality Chemicals Limited has disclosed unaudited financial results for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025, which together make up the first three quarters of FY 2025-26 (FY26). The key financial takeaway is simple: revenue from operations was reported at ₹0 crore in each of these quarters, while losses continued. The update matters because it sets the first reported operating picture after the company’s formal exit from the Corporate Insolvency Resolution Process (CIRP). It also anchors investor expectations ahead of the pending set of audited results for the quarter ended March 31, 2026 (Q4 FY26). Alongside the financials, the company’s disclosures referenced multiple governance dates, including a Monitoring Committee meeting on May 27, 2026. Market context was also provided through stock price references during 2026.

CIRP exit and the NCLT approval date

Omkar Speciality Chemicals stated that it has formally transitioned out of CIRP after the National Company Law Tribunal (NCLT) approved its resolution plan on July 31, 2025. The company’s disclosures frame subsequent reporting and governance actions as part of the post-resolution phase. A resolution plan amount of ₹26.65 crore was referenced in the provided material. The same material also stated that by September 2025, ₹9.734 crore had already been infused. These data points are important because they indicate that the company’s financial reporting for FY26 Q1-Q3 occurred after a legal and governance reset, but before any visible recovery in operating revenue.

Unaudited results for FY26 Q1 to Q3

For FY26 Q1, Q2, and Q3, Omkar Speciality Chemicals reported revenue from operations of ₹0 crore across the board. The company also reported net losses in each quarter: ₹0.41 crore in Q1, ₹0.52 crore in Q2, and ₹0.33 crore in Q3. Separately, the company highlighted that the Q3 net loss was ₹32.84 lakh, which is approximately ₹0.33 crore, aligning with the quarterly loss figure disclosed elsewhere. The material also noted that losses ranged from ₹0.3284 crore to ₹0.5179 crore per quarter, consistent with the above numbers. In addition, basic EPS for these quarters was stated to be in a range of negative ₹0.16 to negative ₹0.25.

One-quarter detail also cited in another format

In the provided material, a separate earnings reference for the quarter ended June 30, 2025 stated revenue of INR 0.086 million and net loss of INR 4.1 million. Normalised to ₹ crore, this implies revenue of about ₹0.0086 crore and a net loss of about ₹0.41 crore. This sits alongside the company’s ₹0 crore revenue-from-operations line for the same period, which is consistent if the revenue figure was rounded in the summary presentation. The same reference stated a basic loss per share from continuing operations of INR 0.2 and diluted loss per share of INR 0.2 for that quarter.

Quarterly performance snapshot (as disclosed)

Monitoring Committee and board meeting references

The disclosures stated that the company’s Monitoring Committee would meet on May 27, 2026 to approve unaudited financials for the quarters ended June, September, and December 2025. The material also stated that the Monitoring Committee approved unaudited financial results for Q1, Q2, and Q3 FY26. Separately, the provided information also referred to a “latest board meeting” taking place on May 27, 2026 for the purpose of “Audited Results.” Taken together, the May 27, 2026 date is presented as a key checkpoint in the company’s post-CIRP reporting calendar, with multiple references tied to financial approvals.

A separate exchange-related entry also referred to a Board of Directors meeting scheduled on June 12, 2026, with the purpose including audited financial results as on March 31, 2026. This adds another date that investors may track alongside the company’s stated intention to announce Q4 FY26 financial results for the quarter ended March 31, 2026.

Restructuring and equity reset under the resolution plan

Beyond quarterly results, the provided material described a capital restructuring that includes cancellation of existing equity shares and issuance of new equity to IFFAS Kshitij SPV LLP. It stated that the monitoring committee convened on April 15, 2026 and set April 29, 2026 as the record date for extinguishment and cancellation of all existing equity shares. The disclosure described that, on the record date, all shares held by promoters, promoter groups, and public shareholders (face value ₹10) would be cancelled.

The same material stated that the company would issue 50 lakh new equity shares to IFFAS Kshitij SPV LLP at par value on a private placement basis, raising ₹5 crore in cash, and resulting in IFFAS Kshitij SPV LLP assuming complete ownership of Omkar Speciality Chemicals. These restructuring steps are presented as part of the NCLT-approved framework, and form a key part of the post-CIRP transition described in the disclosures.

Stock price context cited in the material

The provided material cited the company’s share price at ₹3.6 as of June 4, 2026. Another market snapshot referenced ₹3.41 on April 28, 2026 (with a -4.75% move indicated for that day’s quote). These datapoints were included as context for where the stock traded during the post-CIRP transition period and around the time when financial approvals and restructuring steps were being communicated.

What is pending: Q4 FY26 results and dividend consideration

The company is preparing to announce Q4 FY26 financial results for the quarter ended March 31, 2026. The provided material stated that Q4 FY26 results were scheduled for May 2026 (Expected). It also stated that the board of directors would meet on that date to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. Separately, an exchange entry referred to a June 12, 2026 board meeting for audited financial results as on March 31, 2026, reinforcing that audited reporting for FY26 is a near-term milestone referenced across disclosures.

Market impact and why these numbers matter

From the disclosed numbers, the immediate market-facing issue is the absence of operating revenue across three consecutive quarters in FY26, even as quarterly losses continued. The reported losses of ₹0.33 crore to ₹0.52 crore indicate ongoing costs while the company remains in a transition phase. The restructuring steps also matter for shareholders because the disclosures explicitly describe cancellation of existing equity and issuance of new shares to a single entity, which is a material change in ownership and capital structure. In such a setting, investors typically focus on the timing and content of audited results for March 31, 2026, and on whether subsequent disclosures show resumption of operating activity.

Key facts at a glance

Conclusion

Omkar Speciality Chemicals’ unaudited FY26 Q1-Q3 results show a post-CIRP operating picture defined by nil revenue from operations and continuing quarterly losses. The disclosures also highlight key governance dates, including the Monitoring Committee meeting on May 27, 2026 and board-related references tied to audited results for March 31, 2026. Separately, the company’s capital restructuring plan outlines cancellation of existing shares and issuance of new equity to IFFAS Kshitij SPV LLP, alongside a ₹5 crore cash raise through the new issue. The next confirmed reporting focus, based on the provided material, is the company’s audited financial statements for the quarter ended March 31, 2026 and the scheduled communication around Q4 FY26 results.